In-Hospital Costs and Costs of Complications of Chronic Total Occlusions

Is a chronic total occlusion worth rechanneling? This question can often be found in different studies, all of them with clinical endpoints. This study (soon to be published in J Am Coll Cardiol Intv.) analyzes another aspect: costs, not only derived from materials used for a successful procedure, but also from materials and hospital stay in case of complications.

Costos hospitalarios y de las complicaciones de las oclusiones totales crónicasResearchers calculated costs for 964 patients, from 12 sites, included in the OPEN-CTO (Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion Hybrid Procedures) registry. Data were collected prospectively. A multivariate model was developed to estimate the higher costs derived from prolonged length of stay due to complications.

 

Mean costs for the index hospitalization were USD 17,048 ± 9904. About 14.5% of patients experienced at least one complication.


Read also: We Must Still Fear the “Big Five Complications” After TAVR.


Obviously, patients with complications had higher hospital costs (about 50% higher) and a 1.5-day longer hospital stay than patients without complications.

 

Seven complications were independently associated with a direct increase of costs and 6 were associated with prolonged stay.

 

Significant perforations and peri-procedural infarctions were the events that increased costs the most.


Read also: El acceso transcavo es seguro en el TAVI.


These costs may entail very different realities depending on where we practice medicine, so there is no possible generalization. Regardless, a cost-benefit analysis beyond money must be applied to all patients. As regards total occlusions, clinical criteria must reign. In cases with high ischemic burden in symptomatic patients, we should at least attempt the procedure, even if it is technically difficult. The opposite case would be a very simple lesion without evident ischemia (no invasive or non-invasive evidence) in an asymptomatic patient. We should avoid falling into the trap of treating such a lesion.

 

Conclusions

Complications have a significant impact on both costs and length of stay (without considering clinical events) for patients undergoing angioplasty for chronic total occlusion. Methods to identify high-risk patients more clearly and to develop strategies to prevent complications may reduce both events and costs.

 

There still are certain angioplasties that we should not even attempt without a careful risk-benefit analysis.

 

Original title: In-Hospital Costs and Costs of Complications of Chronic Total Occlusion Angioplasty. Insights from the OPEN-CTO Registry.

Reference: Adam C. Salisbury et al. J Am Coll Cardiol Intv 2019, article in press.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

High Ischaemic Risk Criteria in Chronic Coronary Syndrome: Prevalence and Prognosis

Despite advances in the management of chronic coronary syndrome (CCS), including the widespread use of drug-eluting stents (DES) and the optimization of medical therapy,...

ACC 2026 | DKCRUSH VIII: IVUS or angiography to guide PCI in complex coronary bifurcations

Intracoronary imaging guidance has become an established recommended strategy in complex coronary lesions. In the specific setting of complex bifurcations, uncertainty remained regarding the...

ACC 2026 | OPTIMAL: IVUS Guidance in PCI of the Unprotected Left Main Coronary Artery

Percutaneous coronary intervention (PCI) is considered an equivalent alternative to coronary artery bypass surgery in patients with left main coronary artery (LMCA) stenosis and...

ACC 2026 | IVUS-CHIP Trial: Intravascular ultrasound–guided versus angiography-guided complex PCI

Optimization of percutaneous coronary intervention (PCI) in complex lesions remains a relevant clinical challenge. In this context, the IVUS-CHIP trial was designed to evaluate...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

High Ischaemic Risk Criteria in Chronic Coronary Syndrome: Prevalence and Prognosis

Despite advances in the management of chronic coronary syndrome (CCS), including the widespread use of drug-eluting stents (DES) and the optimization of medical therapy,...

Management of Valve Thrombosis in TAVI: Current Evidence-Based Approach

The expansion of transcatheter aortic valve implantation (TAVI) into younger and lower-risk populations has brought bioprosthetic valve thrombosis to the forefront as a clinically...

Experience with the intra-annular self-expanding Navitor valve: data from the STS/ACC TVT registry

The expansion of TAVI, with the introduction of new-generation devices, has prioritized not only periprocedural safety, but also the preservation of coronary access, more...